WEBSITE BSE:512036 NSE: SKYBIOTECH Inc. Year: 1983 Industry: Textile My Bucket: Add Stock
Last updated: 00:00
No Notes Added Yet
Skybiotech Healthcare Ltd. is a pharmaceutical and healthcare company engaged in the manufacturing, marketing, and trading of pharmaceutical formulations and healthcare products. The company’s product portfolio typically includes tablets, capsules, syrups, injectables, and other therapeutic formulations across key segments such as antibiotics, pain management, nutraceuticals, and general healthcare. Skybiotech operates with a focus on quality-compliant manufacturing and often works through a distribution network of stockists, wholesalers, and...Read More
Skybiotech Healthcare Ltd. is a pharmaceutical and healthcare company engaged in the manufacturing, marketing, and trading of pharmaceutical formulations and healthcare products. The company’s product portfolio typically includes tablets, capsules, syrups, injectables, and other therapeutic formulations across key segments such as antibiotics, pain management, nutraceuticals, and general healthcare. Skybiotech operates with a focus on quality-compliant manufacturing and often works through a distribution network of stockists, wholesalers, and medical representatives to reach doctors, hospitals, and retail pharmacies. The company may also be involved in contract manufacturing and third-party marketing, which allows it to expand its product reach without heavy branding costs. Its business performance is influenced by regulatory compliance, pricing controls, competition from larger pharma players, and demand conditions in domestic healthcare markets. As a small pharmaceutical player, Skybiotech Healthcare Ltd. offers growth potential driven by increasing healthcare awareness and medicine demand, but it also faces risks related to scale, intense competition, and margin pressures in the pharma industry ...Read Less
Our experts help you choose the right stocks based on performance, risk, and growth potential.
Market Cap ₹27 Cr.
Stock P/E -11.2
P/B 3.2
Current Price ₹138.9
Book Value ₹ 43
Face Value 10
52W High ₹237.3
Dividend Yield 0%
52W Low ₹ 116.5
Price goes above X
Price falls below X
PE goes above X
PE falls below X
₹ | |
| #(Fig in Cr.) | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|
| Net Sales | 0 | 0 | 2 | 3 | 1 | 2 | 2 | 1 |
| Other Income | 1 | 0 | 0 | 0 | -0 | 0 | 0 | 0 |
| Total Income | 1 | 0 | 2 | 3 | 1 | 2 | 2 | 1 |
| Total Expenditure | 0 | 0 | 2 | 3 | 2 | 2 | 2 | 1 |
| Operating Profit | 1 | 0 | 0 | -0 | -1 | 0 | -0 | -0 |
| Interest | 0 | 0 | 0 | 0 | -0 | 0 | 0 | 0 |
| Depreciation | -0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Exceptional Income / Expenses | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Profit Before Tax | 1 | 0 | -0 | -0 | -1 | -0 | -0 | -0 |
| Provision for Tax | 0 | 0 | 0 | -0 | -0 | 0 | 0 | 0 |
| Profit After Tax | 0 | 0 | -0 | -0 | -1 | -0 | -0 | -0 |
| Adjustments | 0 | 0 | 0 | -0 | 0 | 0 | -0 | 0 |
| Profit After Adjustments | 0 | 0 | -0 | -0 | -1 | -0 | -0 | -0 |
| Adjusted Earnings Per Share | 2.5 | 1.3 | -1.3 | -2.1 | -5.7 | -0.1 | -1.6 | -2.5 |
| #(Fig in Cr.) | Mar 2025 | TTM |
|---|---|---|
| Net Sales | 7 | 6 |
| Other Income | 0 | 0 |
| Total Income | 7 | 6 |
| Total Expenditure | 9 | 7 |
| Operating Profit | -2 | -1 |
| Interest | 0 | 0 |
| Depreciation | 1 | 0 |
| Exceptional Income / Expenses | 0 | 0 |
| Profit Before Tax | -2 | -1 |
| Provision for Tax | -0 | 0 |
| Profit After Tax | -2 | -1 |
| Adjustments | 0 | 0 |
| Profit After Adjustments | -2 | -1 |
| Adjusted Earnings Per Share | -12.4 | -9.9 |
| # | 1 Year | 3 Year | 5 Year | 10 Year |
|---|---|---|---|---|
| Sales CAGR | 0% | 0% | 0% | 0% |
| Operating Profit CAGR | 0% | 0% | 0% | 0% |
| PAT CAGR | 0% | 0% | 0% | 0% |
| # | 1 Year | 3 Year | 5 Year | 10 Year |
|---|---|---|---|---|
| Share Price CAGR | -27% | 8% | 44% | 4% |
| ROE Average | -26% | -26% | -26% | -26% |
| ROCE Average | -15% | -15% | -15% | -15% |
| #(Fig in Cr.) | Mar 2025 |
|---|---|
| Shareholder's Funds | 9 |
| Minority's Interest | 2 |
| Borrowings | 7 |
| Other Non-Current Liabilities | -1 |
| Total Current Liabilities | 3 |
| Total Liabilities | 19 |
| Fixed Assets | 12 |
| Other Non-Current Assets | 5 |
| Total Current Assets | 2 |
| Total Assets | 19 |
| #(Fig in Cr.) | Mar 2025 |
|---|---|
| Opening Cash & Cash Equivalents | 9 |
| Cash Flow from Operating Activities | -1 |
| Cash Flow from Investing Activities | -10 |
| Cash Flow from Financing Activities | 1 |
| Net Cash Inflow / Outflow | -9 |
| Closing Cash & Cash Equivalent | -0 |
| # | Mar 2025 |
|---|---|
| Earnings Per Share (Rs) | -12.37 |
| CEPS(Rs) | -9.54 |
| DPS(Rs) | 0 |
| Book NAV/Share(Rs) | 46.93 |
| Core EBITDA Margin(%) | -31.97 |
| EBIT Margin(%) | -34.23 |
| Pre Tax Margin(%) | -34.4 |
| PAT Margin (%) | -33.59 |
| Cash Profit Margin (%) | -25.91 |
| ROA(%) | -12.35 |
| ROE(%) | -26.36 |
| ROCE(%) | -14.91 |
| Receivable days | 21.98 |
| Inventory Days | 82.48 |
| Payable days | 62.86 |
| PER(x) | 0 |
| Price/Book(x) | 3.49 |
| Dividend Yield(%) | 0 |
| EV/Net Sales(x) | 5.5 |
| EV/Core EBITDA(x) | -20.73 |
| Net Sales Growth(%) | 0 |
| EBIT Growth(%) | 0 |
| PAT Growth(%) | 0 |
| EPS Growth(%) | 0 |
| Debt/Equity(x) | 0.8 |
| Current Ratio(x) | 0.75 |
| Quick Ratio(x) | 0.13 |
| Interest Cover(x) | -201.13 |
| Total Debt/Mcap(x) | 0.23 |
| # | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|
| Promoter | 62.71 | 62.71 | 62.71 | 62.71 | 62.71 | 63.48 | 63.48 | 63.48 | 63.48 | 63.48 |
| FII | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| DII | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Public | 37.29 | 37.29 | 37.29 | 37.29 | 37.29 | 36.52 | 36.52 | 36.52 | 36.52 | 36.52 |
| Others | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 | 100 |
| # | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|
| Promoter | 0.12 | 0.12 | 0.12 | 0.12 | 0.12 | 0.12 | 0.12 | 0.12 | 0.12 | 0.12 |
| FII | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| DII | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Public | 0.07 | 0.07 | 0.07 | 0.07 | 0.07 | 0.07 | 0.07 | 0.07 | 0.07 | 0.07 |
| Others | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 0.19 | 0.19 | 0.19 | 0.19 | 0.19 | 0.19 | 0.19 | 0.19 | 0.19 | 0.19 |
* The pros and cons are machine generated.
You May Also Know About
Looking to buy unlisted shares or need guidance on the investment process? Our expert Private Equity Advisors are here to assist you with accurate information, real-time pricing, and seamless execution.
Want to sell unlisted shares, liquidate your ESOPs, or understand the step-by-step process of liquidation? Connect with our Buying Team for smooth coordination, quick evaluations, and end-to-end support.
Planning to build or grow your portfolio? For Mutual Fund investments, PMS solutions, tailored portfolio creation, and overall wealth management, our dedicated Wealth Team is ready to guide you.
ChatGPT
Claude
Perplexity
